67,33 €
Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The seventh volume of the book features reviews on these topics:
· Essential oils and monoterpenes as potential anti-cancer agents
· Drug delivery systems and emerging immunotherapeutic strategies for the treatment of glioblastoma
· CTDNA in solid tumors
· Cholesterol treatments (including Pitavastatin) and their potential in cancer treatment
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 393
Veröffentlichungsjahr: 2021
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
Bentham Science Publishers Ltd. Executive Suite Y - 2 PO Box 7917, Saif Zone Sharjah, U.A.E. Email: [email protected]
Frontiers in Clinical Drug Research - Anti-Cancer Agents presents recent developments of various therapeutic approaches against different types of cancer. The book is a valuable resource for pharmaceutical scientists, postgraduate students, and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research.
The five chapters in this volume are written by eminent authorities in the field. Chapter 1 presents the latest research progress in the use of essential oils and monoterpenes as anti-cancer agents. Chapter 2 gives an overview of current innovative approaches to glioblastoma, focusing on the therapeutic benefits of immunotherapeutic agents and drug delivery systems. Chapter 3 summarizes the roles of ctDNA in clinical practice for diagnosis, treatment choices and responses to therapy in various solid cancers. Chapter 4 focuses on the anti-cancer effects of pitavastatin, including its mechanism of action as well as the potential adverse reactions linked to its clinical use. Chapter 5 discusses the biphasic role of cholesterol, in and around the cancer tumor, as a model target for anti-cancer therapeutic management.
I hope that the readers will find these reviews valuable and thought-provoking so that they may trigger further research in the quest for new and novel therapies against cancers.
I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications) and Mrs. Salma Sarfaraz (Senior Manager Publications) at Bentham Science Publishers.
Cancer is a complex disease, and some projections indicate that in 2030, cancer mortality will reach approximately 11.4 million deaths worldwide. One treatment for cancer is chemotherapy. However, cancer cells could present resistance to the therapeutic compounds, and these compounds also have adverse effects. New drugs with anticancer activity have been successfully found in plants. Essential oils (EOs) are a mixture of over 100 volatile organic compounds abundant in aromatic plants. EOs are mainly composed of compounds of low molecular weight, such as monoterpenes, sesquiterpenes, and phenolic compounds. The chemical composition of EOs depends mainly on the plant species, place of origin, and climatic conditions. Generally, the EO density at room temperature is lower than that of water. They are brown, yellow, or colorless, and they have a perceptible aroma. EOs have been used throughout history in different areas, such as in foods, cosmetics, cleaning supplies, and traditional medicine for the treatment of certain health problems. Monoterpenes, built from two isoprene molecules, are hydrocarbon terpenes and oxygenated compounds (terpenoids), such as alcohols, aldehydes, ketones, acids, and esters. Monoterpenes are one of the main chemical constituents of EOs that have appeared in a large number of studies, and their anticancer efficacy has been documented between 2015-2020. This review presents the latest research progress in the use of EOs and monoterpenes as anticancer agents. The 115 EOs and 26 monoterpenes obtained from 36 different plant families included in this review show that Asteraceae and Lamiaceae have been the most studied families during this period.
Cancer is a disease with one of the highest rates of death worldwide. In 2018, 9.6 million deaths were attributed to cancer. Cancer is a disease with significant mortality and morbidity in all regions of the world. The mortality and incidence of cancer are rapidly increasing worldwide. The increase is associated with age and growing population and changes in the prevalence of the main risk factors for cancer [1].
The types of cancer with the highest number of deaths worldwide are lung, liver, gastric, colorectal, and breast cancer. In men, the most frequent type of cancer (the main cause of death) is lung cancer, followed by prostate, colorectal, liver, and stomach cancer. Additionally, in women, breast cancer is the most frequently diagnosed and is the main cause of death, followed by lung and colorectal cancer. Cervical cancer is fourth in incidence and mortality. However, the type of cancer with the highest diagnosis rate and the highest death rate varies between countries depending on economic development, social factors, and the lifestyle of the populations [2].
The main causes of cancer have been determined to be physical (ultraviolet radiation), chemical (asbestos, tobacco smoke, aflatoxins, and arsenic), and biological (viruses, bacteria, and parasites). Cancer development can also be caused by the hereditary genetic load of the body [3].
Cancer is characterized by the accelerated and uncontrolled growth of cells. Cancer defines malignant neoplasms characterized by metastatic growth [4]. It can occur in almost any organ or tissue in relation to a variety of etiological factors, such as genomic instability and environmental stress [4]. During the development of cancer, a multistep process is present, during which genetic alterations confer specific types of growth benefits; these alterations, therefore, drive the progressive transformation from normal cells to malignant cancer cells. Alterations in malignant cell growth are characterized by several key changes. Cells tend to alter their division cycle, presenting the following characteristics: sustaining proliferative signaling, evading growth suppressors, resisting cell death producing angiogenesis, activating invasion to other organs, metastasis, and enabling replicative immortality [5]. Cancer cells can generate a tumor, an irregular mass of tissue, which may or may not be solid, and can be differentiated into malignant or benign forms. Malignant forms can grow rapidly, invade and metastasize, and potentially cause death. There are several treatments of cancer, such as radiation therapy, surgery, hormone therapy, immunotherapy, and chemotherapy. These treatments can be used individually or concomitantly, depending on the stage of advancement of cancer [1]. Chemotherapy is a treatment based on the use of drugs with cytotoxic activity, and in some cases, it can be applied before surgery in order to reduce the size of the tumor. Cytotoxic compounds can induce death in cancer cells, and the type of death that occurs is apoptosis [6]. Cell death by apoptosis aids in tissue homeostasis. This process is carried out by mitochondrial permeabilization and caspase activation. Chromatin condensation and DNA fragmentation are characteristics of apoptotic cells, which are ultimately eliminated by phagocytes. The dysregulation of apoptosis can contribute to pathologies such as cancer, autoimmune or neurodegenerative diseases [7].
More than 80% of chemotherapy drugs have been obtained from plants [8]. These drugs have shown activity against cancer. However, they also produce adverse effects, so alternatives are currently being sought for this disease. EOs and their different constituents have been a new source of cytotoxic and antitumor compounds. Currently, different in vivo and in vitro studies have been performed.
Many cultures have used EOs in religious practices, dating back to as early as 6000 BC. Later, ancient Egyptians used cypress, spikenard, and lotus oils in rituals and placed amphoras containing fragrant oils in the tombs for the voyage to the afterlife [9]. Additionally, they used EOs in medicine, perfumery, and cleansing. In Greece, visions of the oracles at Delphi came through inhalation of the smoke produced by Laurus nobilis [10]. The Greek and the Romans associated fragrances with their gods, but they also used EOs in baths and perfumery. The Persians made great contributions to the knowledge of aromatics and medicine. When the Crusaders returned to Europe, they brought perfumes, aromatics, and remedies unknown to Europeans before. Over the next few hundred years, the range of aromatic medicines became more popular, and the industry of EOs increased, providing oils for fragrance, flavor, and pharmaceutical purposes. In recent years, the therapeutic use of EOs has increased [11].
EOs are defined as highly concentrated aromatic oils of plant origin that are obtained from the leaves, flowers, barks, seeds, fruit peels, and rhizomes. EOs are a complex mixture of low molecular weight compounds, such as monoterpenes, sesquiterpenes, straight-chain aliphatic, aromatic, or heterocyclic compounds, and in some oils, allyl sulfides are found [12]. Many oils contain between a few dozen to 200 compounds. The chemical composition of EOs depends on many factors, such as the climate, season, geographical location, plant maturity, drying method, genetic variation, and stress during growth and storage. Thus, the variability in the EOs composition influences their properties [13, 14]. EOs are obtained by hydro or steam distillation [15], solvent extraction, supercritical fluid extraction [16], or cold pressing process [17].
The function of EOs in plants could be dependent on environmental interactions. Moreover, they play an important role in protecting plants from predators and pathogens [18, 19]. In the agriculture, nutritional, cosmetic, flavoring, and pharmaceutical industries, EOs have a wide range of applications [20, 21] because they have several biological activities, such as analgesic, anti-inflammatory, antimicrobial, repellent, and anticancer activities [22]. Recent studies have reported the antiproliferative and cytotoxic activities of several EOs against different cancer cell lines. For example, the oils of Citrus limon had cytotoxic effects against the T47D, MDA-MB-231 and SH-SY5Y cell lines [23], Schinus terebinthifolius showed activity against HepG2 and Caco-2 cells [24], Boswellia dalzielii was active against OVCAR-3 cells [25], and Cymbopogon flexuosus showed anticancer activity against 502713 and IMR-32 cells and caused apoptosis in the HL-60 cell line [26].
Monoterpenes and monoterpenoids (oxygenated terpene derivatives), representing main EOs components, are the result of the combination of isoprene units (C5H8). Many studies have reported that these compounds have many pharmacological activities, such as wound healing [27], anti-inflammatory [28], and anticancer [29]. For example, myrcene, limonene, and α-phellandrene presented cytotoxic activity against the HCT 116, HepG2, and MCF-7 cell lines [24]. Smaller terpenes like monoterpenes such as geraniol, citral, and linalyl acetate, are obtained by synthetic methods, and many of them are commercially available. Several monoterpenes have been used as excipients in the preparation of nanostructure systems [21].
Several EOs have cytotoxic, antimutagenic, antioxidant, antiogenic activities on cancer cells. The cytotoxic and antitumoral effects involved multiple pathways (Fig.1), such as induction of apoptosis, antiproliferative activity, modulation of DNA damage, MDR reduction. Different studies have found that EOs have cell membrane permeability. EOs are capable of diminishing phase I enzymes such as cytochrome (CytC) and increase phase II enzymes such as glutathione (GSH), preventing oxidative damage. Also these oils can interrupt mitochondrial membrane potential resulting in a decrease of GSH and increase of reactive oxygen species (ROS) and reactive nitrogen species (RNS), caspase 3, and caspase 9 activity, causing apoptosis. Other pathways such as mTOR (mammalian target of rapamycin), Akt (Phosphoinositol-3-kinase (PI3K) / protein kinase B), PARP (Poly (ADP-Ribose) polymerase), AP1 (Activator protein-1), NF-ⱪB (Nuclear factor kappa-light-chain-enhancer of activated B cells), Bcl-2 (B cell lymphoma protein) are altered by EOs to induce apoptosis in cancer cells [30].
Fig. (1)) Induction of apoptosis in cancer cells by alteration of multiple pathways caused by EOs. Mouse double minute 2 homolog (Mdm), CDK-interacting protein 1 (p21), Mitogen-activated protein kinases (MAPK).The aim of this review is to provide an overview of studies on the potential cytotoxic and antitumoral activities of 115 EOs of 106 different species and to present the main components of these EOs, along with the inclusion of 26 monoterpenes with cytotoxic effects Table 1.
Table 2 shows the cytotoxic and antitumoral activities of 26 monoterpenes, which have been evaluated in different in vitro and in vivo models.
This review discusses research from the last 5 years on EOs and monoterpenes which exhibit cytotoxic and anticancer activities. The EOs that were active were mostly isolated from the Lamiaceae and Myrtaceae families.
The National Cancer Institute of the United States of America considers that pure compounds or extracts with IC50 values lower than 4 µg/mL and 30 µg/mL, respectively, are considered cytotoxic [124]. Based on this, not all EOs can be considered to be cytotoxic agents. However, they can be employed to aid in the treatment of this disease.
In this work, the studies of cytotoxic activity of plants belonging to 36 families and a total of 106 different species are presented. However, only 19 species have IC50 values in accordance with those established by the National Cancer Institute (NCI). Only 6 monoterpenes showed cytotoxic values below the parameters established by the NCI.